Bayer CEO Marijn Dekkers

9. Bayer HealthCare
2014 revenue: €19.975 billion ($25.47 billion)
2013 revenue: €18.924 billion ($24.17 billion)

Bayer's been counting on its top 5 drugs to take it far, and they lived up to their billing in 2014. Anticoagulant Xarelto, eye med Eylea, cancer-fighters Stivarga and Xofigo and pulmonary arterial hypertension drug Adempas combined for €2.9 billion in sales last year, just topping forecasts to help the German pharma meet its updated sales guidance of €42 billion.

The Big 5 also helped Bayer's HealthCare subgroup expand by 5.6% on the year to hit €19.98 billion in sales, with pharma growing 11.2%. The other division in HealthCare, Bayer's consumer health business, climbed just 2.1%, but the company expects that to increase as it folds in the Merck ($MRK) OTC unit it purchased last year for $14.2 billion.

Both pharma and OTC will play increasingly important roles for the Leverkusen-based drugmaker come later this year, when it expects to spin off its plastics unit. Other than HealthCare, CropScience--an agriculture business that ballooned 7.7% last year to reach sales of €9.49 billion--will be the only puzzle piece remaining, which Bayer is planning to streamline and rebrand as a life sciences company.

Even without MaterialScience, though, the pharma expects to see sales increase; it expects approximate sales of €46 billion in 2015, with close to €4 billion of that coming from the powerhouse group of new drugs.

 -- Carly Helfand (email | Twitter)

For more:
Ambitious Bayer puts up $27B sales goal for 2017, with OTC carrying a big load
Bayer counts on consumer health, pharma growth to power 2015
Bayer rolls up its sleeves for major reorg after plastics unit departs
Bayer aims to crush consumer health rivals with $14B Merck unit buyout
Brandicourt's departure piles on the exec shuffling at Bayer


Suggested Articles

Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction.

Several of GlaxoSmithKline's vaccines are riding strong momentum and now the drugmaker is selling two assets to focus on those growth products.

AstraZeneca’s Farxiga is chasing an OK to treat heart failure regardless of a diabetes diagnosis. But in the meantime, it's scored a smaller nod.